Delving into the Latest Updates on Z-100 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Ancer20, SSM, 结核杆菌热水提取物

+ [5]

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication

Leukopenia

Inactive Indication

HIV InfectionsLocally Advanced Cervical Carcinoma

Originator Organization

Zeria Usa, Inc.

Active Organization

Zeria Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (28 Jun 1991),

Leukopenia

Regulation-

Login to view timeline

This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.

Start Date01 Dec 2014

Sponsor / Collaborator

Zeria Pharmaceutical Co., Ltd.

JPRN-JapicCTI-121893

/ Unknown statusNot Applicable

Clinical Pharmacology Study of Z-100 - Study on Immunological Parameter in Healthy Adult -

Start Date12 Jul 2012

Sponsor / Collaborator

Zeria Pharmaceutical Co., Ltd.

100 Clinical Results associated with Z-100

Login to view more data

100 Translational Medicine associated with Z-100

Login to view more data

100 Patents (Medical) associated with Z-100

Login to view more data

157

Literatures (Medical) associated with Z-100

01 Nov 2024·Operative Dentistry

Bacterial Adhesion and In Situ Biodegradation of Preheated Resin Composite Used as a Luting Agent for Indirect Restorations

Article

Author: Gonçalves, GGA ; Monteiro, GQdeM ; De Brito, OFF ; Bezerra, ALCA ; Stamfor, TCM ; Alves, LC

SUMMARYObjective:To evaluate surface roughness and bacterial adhesion after in situ biodegradation of the cementation interface of indirect restorations cemented with preheated resin composite.Methods and Materials:Resin composite blocks (Z250XT/3M ESPE) were cemented to bovine enamel (7 × 2.5 × 2 mm) using preheated microhybrid resin composites: (1) Filtek Z100 (3M ESPE) (Z100); (2) Gradia Direct X (GC America) (GDX); and (3) Light-cured resin cement RelyX Veneer (3M ESPE) (RXV) (n=21). The resin composites were preheated on a heating device (HotSet, Technolife) at 69°C for 30 minutes. Disk-shaped specimens (7 × 1.5 mm) were made for biodegradation analysis with the luting agents (n=25). The in situ phase consisted of 20 volunteers’ using an intraoral palatal device for 7 days. Each device had six cylindrical wells for the blocks and the disk-shaped specimens. Biodegradation was evaluated through surface roughness (Ra), scanning electron microscopy (SEM) micromorphological analysis, and colony-forming unit (CFU) count. The film thickness of the luting agents was also measured under stereomicroscopy.Results:Increased surface roughness was observed after the cariogenic challenge without differences between the luting agents. Higher variation and surface flaws suggestive of particulate detachment were observed for Z100. No differences were observed in CFU counts.Conclusions:All materials underwent surface biodegradation, and the surface roughness of the resin cements was similar to or lower than that of the preheated resin composites. The resin composites’ film thickness was thicker than that of the resin cement. Clinicians should be aware of these factors when choosing the use of preheated resin composite since it can lead to reduced longevity of the cementation interface and, therefore, restorations.

01 Oct 2024·European Journal of Public Health

Are educational aspirations associated with susceptibility to smoking, e-cigarette use, and smokeless tobacco use in adolescence?

Article

Author: Ruokolainen, Otto ; Ollila, Hanna ; Konttinen, Hanna ; Karvonen, Sakari

AbstractThe early socio-economic differences in smoking build on the interplay between individual-, family-, peer-, and school-related factors. The present study aimed to add knowledge to this by examining susceptibility to smoking (S-SM), electronic cigarette (e-cigarette) use (S-EC), and smokeless tobacco (snus) use (S-SN) by educational aspirations in a country with advanced tobacco control policies. National cross-sectional School Health Promotion study survey was conducted among 8.–9. grade students (av. 15-year-olds) in 2017 with no prior smoking (n = 47 589), e-cigarette use (n = 49 382), or snus use (n = 53 335). Gender-stratified, age-adjusted multilevel logistic regression analyses with S-SM, S-EC, and S-SN were considered as outcomes and student- and school-level (aggregated) factors were considered as independent variables. The highest prevalence was observed for S-EC (girls 29%, boys 35%), followed by S-SM (16%, 15%) and S-SN (10%, 16%). Compared to those planning for general upper secondary education, S-SM was the highest for those without educational aspirations (OR = 1.20, 95% CI = 1.04–1.40), S-EC for those planning for vocational education [1.15 (1.05–1.25)], and S-SN for those planning for extra year/discontinuation [1.65 (1.04–2.60)] among girls. Among boys, both S-SM [1.37 (1.23–1.52)] and S-EC [1.19 (1.09–1.29)] were the highest among those planning for vocational education, with no clear associations with S-SN. Current other tobacco/e-cigarette use [OR range 1.27–8.87], positive attitude towards product use in one’s age group [3.55–6.63], and liking school [0.58–0.68] consistently associated with susceptibility. Students not planning for academically oriented education had higher susceptibility to different nicotine products. High S-EC warrants monitoring to strengthen policy evaluation and prevention.

01 Apr 2024·Journal of Conservative Dentistry and Endodontics

Effect of preheating on the viscosity of composite resins

Article

Author: Poubel, Déborah Lousan do Nascimento ; Garcia, Fernanda Cristina Pimentel ; da Silva, Raquel Cardoso ; Ribeiro, Ana Paula Dias

AbstractAim:To determine the effects of time and temperature on the viscosity of preheated composite resins.Materials and Methods:Eleven composite resins were heated to 60°C, and temperature analyses were performed at intervals of 1 min until they had cooled to 25°C. The permanent oscillatory shear test was performed at 25°C, 35°C, 50°C, and 60°C for three composite resins under a shear rate of 1s−1. One- and two-way analysis of variance were used for the analysis (α = 0.05).Results:There was no significant interaction between the composite resin and time (P = 0.9304), and only the main effect time was significantly different (P < 0.0001). A difference was observed between T0 and T6 (P < 0.001), but not after T7. The increase in temperature resulted in a viscosity reduction (P < 0.05). At 25°C, Beautifil II presented higher viscosity. Palfique LX5 showed a significant viscosity reduction with increasing temperature compared with the others (P < 0.05). For Beautifil II and Z100, there was no difference at temperatures of 50°C and 60°C, while for Palfique LX5, no statistical difference was observed at 35°C, 50°C, and 60°C.Conclusions:Ten minutes of preheating were sufficient to reach a temperature of 60°C, reducing viscosity by at least 84%. However, 5 min after removal, the composite resin cooled to room temperature.Clinical Significance:Preheating composite resin has potential benefits. To determine how this approach will work in clinical practice, it is important to define the effects of time and temperature in the protocol of this technique and understand its limitations.

100 Deals associated with Z-100

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leukopenia	Japan	Zeria Pharmaceutical Co., Ltd.	28 Jun 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Cervical Carcinoma	IND Application	Singapore	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	IND Application	Malaysia	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	IND Application	South Korea	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	IND Application	Thailand	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	IND Application	Vietnam	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	IND Application	Japan	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	Taiwan Province	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
HIV Infections	Discovery	United States	Zeria Pharmaceutical Co., Ltd.	31 Aug 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JPRN-C000000221 (JGOG-DT101, ASCO2013)	Phase 3	Uterine Cervical Cancer	249	Z-100 0.2 μg	(xtmndvecqg) = xxjcmeghui erbxzevpbn (copsplzjrt, 66.4 - 82.8)	Positive	20 May 2013
				Placebo	(xtmndvecqg) = edqzcyodne erbxzevpbn (copsplzjrt, 56.2 - 73.8)